SABCS 2016: systemic therapy for metastatic breast cancer

被引：6

作者：

Gampenrieder S.P. ^{[1
,2
,3
]}

Rinnerthaler G. ^{[1
,2
,3
]}

Greil R. ^{[1
,2
,3
]}

机构：

[1] IIIrd Medical Department, Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, Salzburg

[2] Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg

[3] Cancer Cluster Salzburg, Salzburg

来源：

memo - Magazine of European Medical Oncology | 2017年 / 10卷 / 2期

关键词：

Highlights; Metastatic breast cancer; Review; SABCS; San Antonio Breast Cancer Symposium;

D O I：

10.1007/s12254-017-0326-4

中图分类号：

学科分类号：

摘要：

At the 2016 San Antonio Breast Cancer Symposium, several interesting phase II and phase III studies investigating systemic therapies for metastatic breast cancer were presented. The PrEGOC 0102 trial demonstrated that the combination of fulvestrant plus everolimus is safe and effective and could be an alternative to exemestane plus everolimus for selected patients with hormone-receptor positive, HER2-negative disease. The pan-PI3K inhibitor buparlisib showed some activity in combination with fulvestrant after failure of everolimus in the BELLE-3 trial. PIK3CA mutation detected in circulating tumor DNA (ctDNA) was predictive for a buparlisib efficacy. Unfortunately, the unfavorable toxicity profile precludes further development of this drug. Nonetheless, PI3K seems to be a valid target in tumors resistant to mTOR inhibition. The BROCADE phase II trial failed to show a statistically significant benefit by the addition of the PARP inhibitor veliparib to carboplatin and paclitaxel in patients with BRCA1/2 germline mutation. The overall response rate, however, was statistically significant higher in the veliparib arm compared to the placebo arm. Data from the phase III trial BROCADE-3 are awaited. Finally, the TNT trial did not identify further biomarkers, in addition to BRCA1/2 germline mutation, for carboplatin benefit in patients with metastatic triple-negative breast cancer. © 2017, The Author(s).

引用

页码：86 / 89

页数：3

共 7 条

[1]

Kornblum N.S., Manola J., Klein P., Et al., PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormon e receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy, (2016)

[2]

Di Leo A., Seok Lee K., Ciruelos E., Et al., BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2−, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment, (2016)

[3]

Han H.S., Dieras V., Robson M.E., Et al., Efficacy and tolerability of veliparib (V

[4]

ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: a randomized, phase 2 study, (2016)

[5]

Arpino G., Ferrero J.M., de la Haba-Rodriguez J., Et al., Primary analysis of PERTAIN: a randomized, two-arm, openlabel, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer, 39th San Antonio Breast Cancer Symposium (SABCS), San Antonio, (2016)

[6]

Tutt A., Cheang M.C.U., Kilburn L., Et al., BRCA1 methylation status, silencing and treatment effect in the TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012), (2016)

[7]

Tutt A., Ellis P., Kilburn L., Et al., TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012), (2014)

← 1 →